Łukasz Woźniacki

Dr. Łukasz Woźniacki

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2020 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
KZKatarzyna Zybert
Katarzyna Zybert
ŁWŁukasz Woźniacki
Łukasz Woźniacki
ATAgnieszka Tomaszewska‐Sobczyńska
Agnieszka Tomaszewska‐Sobczyńska
KWKatarzyna Wertheim-Tysarowska
Katarzyna Wertheim-Tysarowska
KCKamila Czerska
Kamila Czerska
DSDorota Sands
Dorota Sands

13 November 2009 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
ŁWŁukasz Woźniacki
Łukasz Woźniacki
TZT. Zubilewicz
T. Zubilewicz

22 December 2021 in Jornal de Pediatria
Verified
Journal Article
Open access
KZKatarzyna Zybert
Katarzyna Zybert
UBUrszula Borawska-Kowalczyk
Urszula Borawska-Kowalczyk
ŁWŁukasz Woźniacki
Łukasz Woźniacki
MDMalwina Dawidziuk
Malwina Dawidziuk
MOMariusz Ołtarzewski
Mariusz Ołtarzewski
DSDorota Sands
Dorota Sands
To present signs and symptoms and clinical course in cystic fibrosis patients with false-negative newborn screening (CF NBS). All children presented in this paper were covered by CF NBS. The group of 1.869.246 newborns was screened in the Institute of Mother and Child in Warsaw within a period of 01.01.1999 – 31.05.2019. Screening protocols evolved over time from IRT/IRT to IRT/DNA/EGA. The authors identified 11 patients with false-negative NBS, in whom CF was diagnosed based on clinical symptoms or the examination of siblings with positive CF NBS. In the study group, the diagnosis was made significantly later in comparison to positive CF NBS patients ranging from 2 months to 15 years of age. CF NBS strategy does not significantly affect the sensitivity of the screening. In the presence of clinical symptoms, additional diagnostics must be implemented, in spite of the negative screening results. At first, the sweat test should be conducted, followed by a DNA analysis of the most common mutations in the given population. The diagnostic process requires searching for CFTR mutations not typically associated with a high chloride concentration in sweat. Repetition of sweat chloride concentration enables the diagnosis in children whose initial chloride values in sweat are borderline, and no CF-causing mutations are detected. In strong clinical indications, the extension of DNA analysis (EGA) is recommended in order to identify rare CF variants. In children with meconium ileus, genetic analysis is mandatory.

23 August 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
PDPavel Drevinek
Pavel Drevinek
KSKatarina Stepankova
Katarina Stepankova
ŁWŁukasz Woźniacki
Łukasz Woźniacki
AHAdrien Halasz
Adrien Halasz
GPGuergana Petrova
Guergana Petrova
DSDorota Sands
Dorota Sands

1 January 2009 in Cases Journal
Verified
Journal Article
Open access
PDF file
Stanisław NiemczykStanisław Niemczyk
Stanisław Niemczyk
EFEwa Filipowicz
Ewa Filipowicz
ŁWŁukasz Woźniacki
Łukasz Woźniacki
JGJanusz Grochowski
Janusz Grochowski
LZLeszek Zaleski
Leszek Zaleski
JRJoanna Matuszkiewicz Rowinska
Joanna Matuszkiewicz Rowinska
Whipple disease is a rare systemic infection caused by Tropheryma whippelii that usually manifests with joint pain, weight loss, diarrhoea and abdominal pain. However, in some cases the infection may involve other organs and tissues.

10 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KWKatarzyna Walicka-Serzysko
Katarzyna Walicka-Serzysko
MPMagdalena Aleksandra Postek
Magdalena Aleksandra Postek
MMMonika Mielus
Monika Mielus
UBUrszula Borawska-Kowalczyk
Urszula Borawska-Kowalczyk
JMJustyna Milczewska
Justyna Milczewska
DSDorota Sands
Dorota Sands
Background/Objectives: Cystic fibrosis transmembrane conductance regulator modulator (mCFTR) therapy has been proven efficacious in controlled clinical trials for individuals with cystic fibrosis. This post-approval retrospective study aimed to determine the comprehensive effects of elexacaftor/tezacaftor/ivacaftor (ETI) on nutritional status, the respiratory system and quality of life over 12 months of clinical use in paediatric patients treatment-naïve to mCFTR. Methods: A retrospective analysis of records of CF adolescents on ETI therapy was conducted. The selected parameters of anthropometric measurements, body composition assessed by BIA, spirometry, and multiple breath nitrogen washout (MBNW) to measure lung clearance index (LCI), were evaluated before therapy and at 3 and 12 months after treatment initiation. Additionally, children completed the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Results: Over 18 months, data from 58 patients (mean age 14.34 ± 1.70, 50% female; 43% homozygous F508del) on ETI were collected. Body weight increased significantly over 12 months, with a mean gain of 3.33 kg at 3 months (p < 0.001) and 7.10 kg at 12 months (p < 0.001), alongside improvements in BMI z-score, fat-free mass, and fat mass. Significant changes (p < 0.001) were also observed after 3 and 12 months in ppFEV1 (8.91 ± 8.23; 9.67 ± 8.77) and ppFVC (4.46 ± 5.24; 4.61 ± 5.70), with a decrease in LCI (−1.62 ± 2.15; −1.68 ± 1.89). The CFQ-R Respiratory score increased by 11.75 points and correlated with most of the pulmonary and nutritional parameters. Conclusions: In real-world settings, clinical improvement during ETI therapy reflects a comprehensive impact on nutritional status, body composition, pulmonary function, and quality of life for adolescents with CF.